Efficacy of Artesunate + Amodiaquine Four Years After Its Introduction in Zanzibar
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00465257
(Due to lack of malaria patients in Zanzibar the study has been suspended.)
The purpose of this study is to assess the efficacy of artesuante + amodiaquine four years after its introduction as first line treatment for uncomplicated childhood malaria in Zanzibar. The hypothesis is that the treatment has a polymerase chain reaction (PCR)adjusted parasitological cure rate of at least 85% 42 days after treatment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
6 Months to 59 Months (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age below 60 months
No general danger signs or severe malaria present (see 22.214.171.124 & 126.96.36.199)
History of fever within 24 hours OR axillary temperature ≥ 37.5Cº
No other cause of fever is detectable
No severe malnutrition
Presence of P. falciparum asexual parasite density between 2000- 200,000/ul
Guardian/Patient has understood the procedures of the study and is willing to participate
Patient able to come for stipulated follow up visits and has easy access to the Study Site
Not able to drink or breastfeed
Recent history of convulsions
Lethargic or unconscious
Unable to sit or stand (as appropriate for age)
History of allergy to test drugs
History of intake of any drugs other than paracetamol and aspirin within 3 days